CLOs on the Move

Intabio

www.intabio.com

 
Intabio provides an analytical platform to transform and accelerate the development of biotherapeutic drugs by enabling early product quality characterization and producing profound efficiency gains across all stages of biopharmaceutical development and manufacturing.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Alchemy GS

Alchemy GS is a Mc Lean, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Saltwhistle Technology

Saltwhistle Technology is a Chester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Assurex Health

Assurex Health is a personalized medicine company that specializes in helping physicians determine the right medication for individual patients who have Behavioral Health disorders. The GeneSight analysis is based on pharmacogenomics, the study of the genetic factors that influence an individual`s response to drug treatments.

21st Century Medicine Inc

21st Century Medicine Inc is a Rancho Cucamonga, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MicuRx Pharmaceuticals

MicuRx mission is to discover and develop safer and more convenient antibiotics to combat drug-resistant bacterial infections. Multi-drug resistant (MDR) infections represent a major global threat to the public health, routinely forcing the use of antibiotics with high incidence of adverse effects. To combat resistant infections, physicians may increase dosing of antibiotics, or resort to less safe agents, pushing the safety envelope. Thus, healthcare providers and regulatory agencies increasingly face a difficult choice of balancing the risk of infection against unacceptably high adverse event rates from an effective but relatively toxic antibiotic. For example, in July 2016, FDA imposed a new labeling warning on the toxicity of fluoroquinolones, further restricting the use of this essential class, exemplified by anti-pseudomonal agent ciprofloxacin. Anti-MRSA agent linezolid (Zyvox®) is often used beyond its approved 14-day therapy, resulting in several myelosuppression-associated adverse effects listed in the black box warning for this important drug. MicuRx is addressing the critical need for effective but safer therapeutics by designing novel new compounds with reduced toxicity and adverse events while maintaining excellent clinical efficacy.